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Edited by Veli-Pekka LehtoAbstract Mesenchymal stem cells (MSCs) are capable of
diﬀerentiating into a variety of lineages, including bone, carti-
lage, or fat, depending on the inducing stimuli and speciﬁc
growth and diﬀerentiation factors. It is widely acknowledged
that basic ﬁbroblast growth factor (bFGF) modulates chondro-
genic and osteogenic diﬀerentiation of MSCs, but thorough
investigations of its eﬀects on adipogenic diﬀerentiation are
lacking. In this study, we demonstrate on the cellular and
molecular level that supplementation of bFGF in diﬀerent phases
of cell culture leads to a strong enhancement of adipogenesis of
MSCs, as induced by an adipogenic hormonal cocktail. In
cultures receiving bFGF, mRNA expression of peroxisome
proliferator-activated receptor c2 (PPARc2), a key transcrip-
tion factor in adipogenesis, was upregulated even prior to
adipogenic induction. In order to investigate the eﬀects of bFGF
on PPARc ligand-induced adipogenic diﬀerentiation, the thia-
zolidinedione troglitazone was administered as a single adipo-
genic inducer. Basic FGF was demonstrated to also strongly
increase adipogenesis induced by troglitazone, that is, bFGF
clearly increased the responsiveness of MSCs to a PPARc
ligand.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Multipotent mesenchymal stem cells (MSCs) are present in a
variety of tissues, including bone marrow, blood, muscle, and
adipose tissue [1–4]. MSCs were found to diﬀerentiate into
cartilage, bone, fat, muscle, and other connective tissues [5,6]
depending on culture conditions, which include supplementa-
tion of lineage-speciﬁc inducing agents as well as hormones
and growth factors.
Basic ﬁbroblast growth factor (bFGF) belongs to the family
of heparin-binding growth factors [7]. To date, more than
twenty FGFs have been discovered and FGFs are known to
induce chemotactic, angiogenic, and mitogenic activity and
play an important role in early diﬀerentiation and develop-
mental processes [8,9]. Basic FGF was reported to inﬂuence
diﬀerentiation of MSCs of various species towards diﬀerent
lineages. Addition of bFGF was shown to enhance chondro-
genic and osteogenic diﬀerentiation of avian MSCs [10] and to
retain the diﬀerentiation potential of extensively expanded
human MSCs towards both the chondrogenic and osteogenic
lineage [11]. Using rat MSCs cultivated under varying condi-
tions, the stimulatory eﬀects of bFGF were repeatedly shown
to promote diﬀerentiation towards the osteogenic lineage [12–
14]. In contrast, the eﬀect of bFGF on the adipogenesis of
MSCs is controversially discussed [11,15,16]. However, those
studies were not focused on adipogenesis; instead experimental
conditions were adjusted to the investigation of osteogenesis or
chondrogenesis and adipogenic diﬀerentiation was mainly as-
sessed by morphology.
Thus, the ﬁrst goal of this study was to investigate the eﬀects
of bFGF on the adipogenic diﬀerentiation of rat MSCs in-
duced by an adipogenic hormonal cocktail consisting of
dexamethasone, insulin, 3-isobutyl-l-methylxanthine (IBMX)
and indomethacin. Basic FGF was supplemented in diﬀerent
phases of the culture and adipogenesis was characterized on
the cellular and the molecular level. Remarkably, in these ex-
periments mRNA expression of the peroxisome proliferator-
activated receptor c2 (PPARc2), a key transcription factor in
adipogenesis in vitro and in vivo [17], was elevated in the
bFGF group not only during the course of diﬀerentiation, but
already prior to adipogenic induction. From this result, it was
hypothesized that bFGF can also enhance adipogenesis that is
solely induced by a PPARc ligand. Therefore, the second goal
was to determine the eﬀects of bFGF on adipogenic diﬀeren-
tiation induced by the thiazolidinedione troglitazone, an ac-
knowledged synthetic ligand of PPARc [18].blished by Elsevier B.V. All rights reserved.
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2.1. Materials
If not otherwise stated, chemicals were obtained from Sigma,
Steinheim, Germany. Basic FGF was obtained from R&D Systems
(Minneapolis, MN, USA). Troglitazone and insulin were kindly pro-
vided by Dr. T. Skurk (Deutsches Diabetes Forschungsinstitut,
Duesseldorf, Germany) and Hoechst Marion Roussel (Frankfurt am
Main, Germany), respectively. Cell culture plastics were purchased
from Corning Costar (Bodenheim, Germany).
2.2. Cell culture
Marrow stromal cells were obtained from six-week old male Sprague
Dawley rats (weight: 170–180 g, Charles River, Sulzfeld, Germany).
MSCs were ﬂushed from the tibiae and femora according to the pro-
tocol of Ishaug [19]. Cells were centrifuged at 1200 rpm for 5 min. The
resulting cell pellet was resuspended in basal medium consisting of
DMEM (Biochrom, Berlin, Germany), 10% fetal bovine serum
(Gemini Bio-Products Inc., Calabasas, CA, USA), 1% penicillin/
streptomycin (Invitrogen, Karlsruhe, Germany), and 50 lg/ml ascorbic
acid. Cells were seeded in T75 ﬂasks and cultured at 37 C and 5%
CO2. Cells were allowed to adhere to the substratum for three days.
The ﬂasks were rinsed twice with phosphate-buﬀered saline (PBS, In-
vitrogen, Karlsruhe, Germany) in order to remove non-adherent cells.
In the following experiments, bFGF was supplemented during diﬀerent
periods of the culture (Fig. 1). Culturing the adherent cells, 12 ml of
basal medium with or without 3 ng/ml bFGF was exchanged every 2–3
days until conﬂuence was reached (proliferation phase I, Fig. 1). Cells
were passaged once with 0.25% trypsin and EDTA (Invitrogen, Karl-
sruhe, Germany). For adipogenic diﬀerentiation, cells were seeded at a
density of 30 000 cells/cm2 in either six-well plates (RT-PCR) or 24-well
plates (glycerol-3-phosphate dehydrogenase (GPDH) activity assay,
ﬂow cytometry, and histological staining) and grown to postconﬂuence
for 3 days with or without bFGF (proliferation phase II, Fig. 1).
Subsequently, cells were diﬀerentiated for 8 days either in the presence
or absence of bFGF (diﬀerentiation phase, Fig. 1). In detail, to induce
adipogenic diﬀerentiation, cultures were treated for 3 days with a
hormonal cocktail containing 0.5 mM 3-isobutyl-1-methylxanthine
(IBMX) (Serva Electrophoresis, Heidelberg, Germany), 10 nM dexa-
methasone, 60 lM indomethacin and 10 lg/ml insulin, which was
added to the basal medium. Subsequently, cultures were maintained
for 5 more days in diﬀerentiation medium consisting of basal medium
supplemented with 10 lg/ml insulin. Alternatively, cells treated with or
without bFGF were diﬀerentiated by adding exclusively 5 lM trog-
litazone (instead of the hormonal cocktail) to basal medium. For this
purpose, troglitazone was dissolved in dimethylsulfoxide as a 1000-fold
stock solution, which was administered with each medium change












Fig. 1. Basic FGF supplementation in diﬀerent periods of the cell
culture. MSCs were exposed to bFGF only in proliferation phase II for
3 days (BFB), only in both proliferation phases I and II for 15 days
(FFB), only in the diﬀerentiation phase (BBF), or throughout the
complete culture period (FFF). Cells grown in the absence of bFGF
(BBB) served as a control. Gray boxes represent basal media without
bFGF (B), black boxes represent basal medium supplemented with
bFGF (F).The supplementation scheme of bFGF is depicted in Fig. 1. Brieﬂy,
medium supplemented with bFGF is abbreviated with ‘‘F’’, basal
medium without bFGF with ‘‘B’’. Cultures treated with bFGF only in
proliferation phase II for 3 days are designated as BFB. Addition of
the factor during proliferation phases I and II for 15 days is indicated
as FFB. Supplementation of bFGF exclusively in the diﬀerentiation
phase is abbreviated as BBF and bFGF treatment during the complete
time of cell culture as FFF. Cells grown in complete absence of bFGF
(BBB) served as control. In preliminary experiments (assessment of
adipogenesis by Oil Red O staining), bFGF was additionally supple-
mented only in the proliferation phase I for 12 days. This condition
yielded results similar to those of the group receiving bFGF during
proliferation phases I and II for 15 days (data not shown); conse-
quently, in order to simplify the experimental design, this group
(bFGF in proliferation phase I only) was omitted in the presented
study.
2.3. GPDH activity assay
GPDH activity was measured using a protocol adapted from
Pairault and Green [21]. In brief, cells washed with PBS were scraped
in lysis buﬀer containing 50 mM Tris, 1 mM EDTA, and 1 mM b-
mercaptoethanol on ice. Subsequently, the resulting suspension was
sonicated with a digital soniﬁer (Branson Ultrasonic Coporation,
Danburg, CT, USA). Cell lysates were centrifuged for 5 min at 13 200
rpm at 4 C. Aliquots of the supernatant were mixed with a solution
containing 0.1 M triethanolamine, 2.5 mM EDTA, 0.5 mM b-
mercaptoethanol, 120 lM reduced nicotinamide adenine dinucleotide
(NADH) (Roche, Mannheim, Germany), and 200 lM dihydroxyac-
etonephosphate. Enzyme activity was monitored by measurement of
the disappearance of NADH at 340 nm over 4.2 min. Enzyme ac-
tivity was normalized to the protein content of each sample. Proteins
were determined by the method of Lowry et al. [22]. Proteins were
precipitated using 12% trichloroacetic acid. In alkaline solution,
proteins were solubilized and complexed with a mixture of disodium
tartrate, copper sulfate and folin-ciocalteu reagent (all Merck,
Darmstadt, Germany). Absorption was measured at 546 nm after 30
min incubation.
2.4. Oil Red O staining
Cells were washed once with PBS and ﬁxed with 10% formaldehyde
(Merck, Darmstadt, Germany) overnight. Cells were covered with 3
mg/ml Oil Red O for 2 h. Excess dye was removed with PBS and ﬁ-
nally, cells were ﬁxed with 10% formaldehyde.
2.5. Flow cytometry
This method was carried out using a protocol adapted from Gimble
et al. [23]. Cells were carefully harvested by treatment with 0.25%
trypsin/EDTA and centrifuged at 200 g at 4 C for 5 min. After
washing the pellet with PBS, cells were centrifuged as described above
and resuspended in PBS containing the lipophilic ﬂuorescent dye Nile
Red. Cells were incubated for 30 min on ice. Samples were analyzed
with a FACSCalibur ﬂow cytometer (Becton–Dickinson, Heidelberg,
Germany). Nile Red ﬂuorescence was measured on the FL2 emission
channel through a 585 21 nm band pass ﬁlter, following excitation
with an argon ion laser source at 488 nm. For each sample, 104 cells
were collected. To determine the number of adipocytes in each sample,
a selection marker M1 was set in histograms. The amount of adipo-
cytes was assessed by determining the percentage of cells within the M1
region.
2.6. Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was harvested from the cells with Trizol reagent (In-
vitrogen, Karlsruhe, Germany) and isolated according to the manu-
facturers instructions. First-strand cDNA was synthesized from total
RNA by using random hexamers (Roche Diagnostics, Mannheim,
Germany) and Superscript II RNase H Reverse Transcriptase (Invitr-
ogen, Karlsruhe, Germany). Samples were incubated at 42 C for 50
min and heated afterwards at 70 C for 15 min to inactivate the en-
zyme. Subsequently, PCR was performed with Sawady Taq-DNA-
Polymerase (PeqLab, Erlangen, Germany); initial denaturation oc-
curred at 94 C for 120 s, ﬁnal extension at 72 C for 30 s for each set of










18S rRNA served as control. Conditions set for the investigated
genes were: 94 C for 45 s, 62 C for 45 s, 72 C for 1 min (36 cycles) for
PPARc2; 94 C for 45 s, 56 C for 45 s, 72 C for 1 min (32 cycles)
for glucose transporter 4 (GLUT4); 94 C for 45 s, 62 C for 45 s, 72 C
for 1 min (36 cycles) for stearoyl-CoA desaturase-1 (SCD-1); and
94 C for 45 s, 56 C for 45 s, 72 C for 1 min (25 cycles) for 18S rRNA.
Reverse transcription and PCR were performed using a Mastercycler
Gradient (Eppendorf AG, Hamburg, Germany). The PCR products
were analyzed by electrophoresis on 2% agarose gels, stained with
ethidium bromide. Finally, the gels were subjected to imaging and
densitometric scanning of the resulting bands under UV light (k ¼ 312
nm) using a Kodak EDAS 290 (Fisher Scientiﬁc, Schwerte, Germany).
2.7. Statistics
Fluorescence-activated cell scanning (FACS) data, GPDH data, and
RT-PCR quantiﬁcation are expressed as means standard deviation.
Single-factor analysis of variance (ANOVA) was used in conjunction
with a multiple comparison test (Tukeys test) to assess statistical sig-
niﬁcance at a level of P < 0:01 for FACS and GPDH data and of
P < 0:05 for RT-PCR data.Fig. 2. Adipogenesis of MSCs on day 8 of diﬀerentiation: assessment
by Oil Red O staining and Nile Red ﬂow cytometry (for quantiﬁ-
cation data, see Table 1). The groups designated as ‘‘not induced’’
were cultivated without induction by the hormonal cocktail (BBB-
not induced: in the absence of bFGF; FFF-not induced: in the
presence of bFGF). All other groups were hormonally induced.
BBB-control was cultivated in the absence of bFGF and served as a
control group. Other cultures were treated with bFGF in prolifer-
ation phase II for 3 days (BFB), in proliferation phases I and II for
15 days (FFB), in the diﬀerentiation phase (BBF), and in complete
culture (FFF), respectively. Scale bar: 50 lm.3. Results
In cultures that did not receive adipogenesis-inducing
agents, no lipid droplets were observed in the absence of bFGF
(Fig. 2 ‘‘BBB-not induced’’, Table 1) and only very few lipid
droplets were detected in the presence of bFGF (Fig. 2 ‘‘FFF-
not induced’’, Table 1). Moreover, the activity of GPDH, a key
enzyme in lipid biosynthesis, was virtually undetectable in the
absence of inducing agents, irrespective of bFGF supplemen-
tation (Fig. 3).
In order to investigate the modulating eﬀects of bFGF,
cultures stimulated by hormonal inducers were supplemented
with bFGF in diﬀerent phases of the cell culture (Fig. 1). In
cultures without bFGF (BBB-control), MSCs only weakly
gave rise to adipocytes after induction with a hormonal
cocktail (Fig. 2): Only about 2% of cultured cells diﬀerentiated
into adipocytes, as determined by FACS analysis (Table 1).
Exposure to bFGF enhanced the adipogenesis of MSCs in all
cases, as determined 8 days after induction by Oil Red O
staining and Nile Red ﬂow cytometry of diﬀerentiated
adipocytes (Fig. 2). Supplementation with bFGF only during
the proliferation phase II (BFB) and during the proliferation
phases I and II (FFB) yielded a 2.8-fold and 6-fold increase of
the fraction of adipocytes, respectively, as compared to BBB-
control (Table 1). The latter resulted in adipocytes containing
the largest lipid droplets of all groups investigated (Fig. 2).
Addition of bFGF in the diﬀerentiation phase only (BBF)
resulted in a 2.3-fold increase of the adipocyte fraction (Table
1), whereas bFGF supplementation during the complete cul-
ture (FFF) yielded the largest increase, i.e., 9.4-fold. Mea-
surement of the GPDH activity supported the observations
with regard to eﬀects of bFGF (Fig. 3). In all induced cultures
supplemented with bFGF, a signiﬁcant increase of GPDH
activity was detected as compared to the BBB control group.
The highest values were again determined for experimental
groups FFB and FFF.
Expression of the adipocyte-speciﬁc genes PPARc2, a key
transcription factor, GLUT4, a glucose transporter and late
Table 1
Quantiﬁcation of ﬂow cytometry analysis
Experimental group FACS (% cells in M1) FACS (relative)
BBB-not induced 0.34 0.06 –
FFF-not induced 1.43 0.65 –
BBB (induced)-control 2.23 0.42 1.00
BFB (induced) 6.21 0.95* 2.78
FFB (induced) 13.46 1.19** 6.03
BBF (induced) 5.07 0.64* 2.27
FFF (induced) 20.90 1.15*** 9.36
To determine the number of adipocytes in each sample, a selection
marker M1 was set in histograms (see Fig. 2). Column 2 represents the
quantiﬁcation of diﬀerentiated adipocytes expressed as a percentage of
total cells in culture, column 3 shows the relative increase as compared
to the control group without bFGF (BBB induced-control). Tukeys
test (n ¼ 4) indicated a statistically signiﬁcant increase as compared to
the control group (BBB) (*), compared to BBB, BFB and BBF (**),
and compared to all groups (***).























Fig. 3. Measurement of GPDH activity on day 3 of diﬀerentiation.
Cultures were treated with bFGF in proliferation phase II for 3 days
(BFB), in proliferation phases I and II for 15 days (FFB), in the dif-
ferentiation phase (BBF), and in complete culture (FFF), respectively.
Cells grown in the absence of bFGF served as control (BBB). GPDH
activity was determined in not induced cultures () and in induced
cultures (j). Tukeys test (n ¼ 4) indicated a statistically signiﬁcant
increase as compared to control group (BBB) (*) and as compared to
BBB, BFB and BBF (**).
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synthesis of unsaturated fatty acids and also a late marker of
adipogenesis, was determined on the mRNA level by RT-PCR
(Fig. 4). Selected experimental groups were investigated in
order to further elucidate the contribution of bFGF to adi-
pogenic diﬀerentiation, i.e., the group receiving bFGF
throughout the entire proliferation phase (FFB) was compared
to the BBB control group.
Gene expression of PPARc2 was assessed one day before
induction (cells grown to conﬂuence), one day and three days
after induction (Fig. 4A). Expression of PPARc2 was in-
creased on day one and day three after induction, as compared
to samples harvested one day prior to induction (Fig. 4A).
PPARc2 expression was elevated in the group receiving bFGF
(FFB) as compared to the control group (BBB); this trend was
observed not only one day and three days after, but also one
day before induction (Fig. 4A).
Additionally, gene expression of late markers of adipogenic
diﬀerentiation, GLUT4 and SCD-1, was assessed on day threeafter induction (Fig. 4B). Again, quantiﬁcation showed that
diﬀerentiation under the inﬂuence of bFGF (FFB) led to an
increased expression of both markers as compared to the
control group (BBB) (Fig. 4B).
When using troglitazone as a single inducer (instead of the
hormonal cocktail), adipogenic diﬀerentiation of MSCs was
also observed. In detail, only weak adipogenesis was detected
in the absence of bFGF (Fig. 5B). Again, the exposure of
MSCs to bFGF throughout the entire culture period resulted
in a strong enhancement of adipogenesis, which was detected
by Oil Red O staining (Fig. 5D) and GPDH activity (Fig. 6). In
general, after induction with troglitazone, intracellular lipid
droplets were distinctly smaller compared to cultures induced
with the hormonal cocktail (Fig. 5), a previously described
phenomenon [24]. Apart from that, with regard to Oil Red O
staining and GPDH activity, troglitazone cultures were com-
parable to corresponding cultures employing the hormonal
cocktail. Hence, adipogenic diﬀerentiation was enhanced by
bFGF to the same extent under both inducing conditions
(Figs. 5 and 6).4. Discussion
Adipogenesis is a complex process involving several tran-
scription factors and signal transduction pathways and is af-
fected by a variety of environmental conditions like growth
and diﬀerentiation factors [17]. In this study, we show that the
growth factor bFGF can strongly enhance adipogenesis of
MSCs induced by a widely used hormonal cocktail consisting
of dexamethasone, IBMX, indomethacin, and insulin.
Besides other features of adipogenic diﬀerentiation (Figs. 2,
3 and 4B), bFGF increased the expression of PPARc2, a key
transcription factor in adipogenesis [17]. As this eﬀect was
observed even prior to adipogenic induction (Fig. 4A), the
hypothesis that bFGF can also enhance adipogenic diﬀeren-
tiation that is induced by a PPARc ligand alone was explored.
Indeed, bFGF enhanced adipogenesis solely induced by trog-
litazone, a commonly recognized PPARc ligand, to the same
extent as that induced by the hormonal cocktail (Figs. 5 and 6).
The eﬀects of bFGF on the hormonal cocktail-induced ad-
ipogenesis of MSCs are inherently more complex to explain.
The inducing eﬀects of dexamethasone and IBMX are still not
well understood and are controversially discussed [17]. How-
ever, indomethacin is commonly acknowledged to be a PPARc
ligand [25]. Furthermore, other experiments using only IBMX
and indomethacin as adipogenic inducers showed enhancing
eﬀects of bFGF similar to those observed in the experiments
employing the complete hormonal cocktail (data not shown).
Therefore, the function of indomethacin as PPARc ligand
suggests that, again, the increase of PPARc2 levels by bFGF
likely contributed to the observed eﬀects.
The obtained results are in agreement with earlier morpho-
logical observations using rat MSCs [16]. The seemingly con-
tradictory results of a diﬀerent report obtained with human
MSCs showing no eﬀect of bFGF treatment may be reason-
ably explained by distinctly diﬀerent adipogenic inducing
schemes [11]. In contrast to our induction phase of 3 days,
Tsutsumi et al. used a similar hormonal cocktail for 25 days
and determined comparable results for groups with and
without bFGF supplement [11]. Additionally, preliminary ex-
periments in our laboratory using human MSCs yielded results
Fig. 4. Assessment of expression of adipocytic genes PPARc2, GLUT4, and SCD-1 using RT-PCR technique. Two experimental groups (BBB and
FFB) were exemplarily investigated to demonstrate the eﬀect of bFGF. Three independent experiments were conducted; representative results of one
experiment are shown here. Additionally, data from semi-quantitative image analysis are depicted. Statistically signiﬁcant diﬀerence between BBB
and FFB group is indicated by *. (A) The expression levels of the transcription factor PPARc2 were determined one day before, one day after and
three days after induction with the hormonal cocktail. 18S RNA was used as control. (B) Gene expression of late markers of adipogenic diﬀeren-
tiation, GLUT4 and SCD-1, was determined on day 3 after induction.
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eﬀects of bFGF on adipogenic diﬀerentiation are not species-
speciﬁc.
In the following, possible mechanisms are discussed through
which bFGF may enhance adipogenesis and result in elevated
PPARc2 expression levels, respectively. First, bFGF may
cause a preferential proliferation of a subpopulation of MSCs
[26,27], e.g., one with enhanced expression of PPARc2. In this
regard, the theoretically possible contribution of diﬀerentiated
adipocytes, which are present in the bone marrow [28], can be
excluded: Mature adipocytes do not attach to the substratum
during cell isolation due to their buoyancy [29] and, in the case
they did so nonetheless, they would be identiﬁed by their
typical phenotype (lipid droplets); furthermore, they have been
demonstrated to be virtually unable to proliferate on culture
plastic substrate [30]. An alternative explanation for enhanced
adipogenesis is that bFGF may exert a direct eﬀect on diﬀer-
entiation or commitment level [26,27], e.g., by directly inducing
or at least maintaining expression levels of PPARc2 mRNA of
MSCs. Basic FGF elevated adipogenesis the most followingsupplementation throughout the complete culture period. The
addition of bFGF only during the proliferation phase (3 days
or 15 days) also resulted in a distinct increase in diﬀerentiation.
These data may be explained with both hypotheses, either the
preferential proliferation of a subpopulation or by direct ef-
fects on the commitment level. However, the enhancing eﬀects
of bFGF on adipogenesis after supplementation to postcon-
ﬂuent cells (BBF) (Figs. 2 and 3) rather support the idea that a
direct eﬀect on the commitment level of MSCs contributes, at
least in part, to the observed extent of adipogenesis. As a
possible mechanism for a direct eﬀect on the commitment le-
vel, Prusty et al. have suggested the MEK/ERK signaling
pathway to play an important role in adipogenesis [31]. Basic
FGF is known to be a potent activator of the MEK/ERK
pathway [8]. Short-term exposure of bFGF (6 h) to 3T3-L1
preadipocytes promoted adipogenesis by phosphorylation of
ERK1/2 and resulted in enhanced PPARc and C/EBPa gene
expression, irrespective of the presence of MEK1 inhibitors
[31]. However, long-term treatment (more than 12–24 h)
of these cells with bFGF, as done in this study, led to an
Fig. 5. Oil Red O staining of diﬀerentiated adipocytes on day 8 of
diﬀerentiation. MSCs were induced with the hormonal cocktail in the
absence (A) and in the presence of bFGF (during complete culture) (C)
or with troglitazone in the absence (B) and the presence of bFGF
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Fig. 6. Measurement of GPDH activity on day 3 of diﬀerentiation.
MSCs were induced with either the hormonal cocktail () or with
troglitazone alone (j). For each induction condition, cells were cul-
tivated either in the absence (BBB) or in the presence of bFGF (during
complete culture) (FFF). Asterisks indicate signiﬁcantly elevated val-
ues as compared to the control group (BBB) (n ¼ 3).
282 M. Neubauer et al. / FEBS Letters 577 (2004) 277–283inhibition of adipogenic diﬀerentiation of 3T3-L1 cells [31].
Overall, the identiﬁcation of the mechanism(s) by which bFGF
exerts its eﬀects on adipogenesis of MSCs may only be eluci-
dated in full by cloning MSCs. Separated MSCs might allow
the exact determination of the response of diﬀerent subsets of
cells to bFGF and adipogenic inducers.
Nevertheless, this study underlines the outstanding role of
PPARc in the adipogenic conversion of MSCs, demonstrated
by the distinct responsiveness of MSCs to the PPARc ligand
troglitazone and the strikingly increased responsiveness pro-
voked by bFGF. This ﬁnding is unexpected because thiazo-
lidinediones alone are not suﬃcient to stimulate eﬃcientdiﬀerentiation, but require to be associated with glucocortic-
oids, insulin and/or IBMX in most culture systems including
preadipocytic systems [32–35]. Thus, MSCs and especially
bFGF-treated MSCs appear to respond in a diﬀerent way to
PPARc activators such as troglitazone as compared to prea-
dipocytic cells.
Moreover, bFGF may play a crucial role in the fate of bone
marrow cells: It has been previously shown that under ap-
propriate culture conditions bFGF can enhance osteogenic
diﬀerentiation [12–14], and it is demonstrated here that given
the required adipogenic environment bFGF also enhances
adipogenesis. Thus, depending on microenvironmental stimuli
and status of lineage-speciﬁc transcription factors, bFGF
present in bone marrow [36] may function as a regulator in the
control of adipogenesis and osteogenesis of MSCs. Further-
more, in several studies an inverse relationship between adi-
pogenic and osteogenic diﬀerentiation in MSC cultures was
demonstrated [37–39]. Therefore, bFGF may modulate the
origin and progression of osteoporosis due to its capability to
sensitize MSCs for an enhanced diﬀerentiation into either os-
teoblasts or adipocytes.References
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